ArticleTherapeutic advances in medical oncology2026
Prognostic impact of baseline blood biomarkers in SCLC first-line treatment.
Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Small cell lung cancer (SCLC) is an aggressive malignancy with poor prognosis despite available treatment options. Although immunotherapy now constitutes the standard of care for extensive-stage SCLC (ES-SCLC), reliable biomarkers for patient stratification remain scarce. Objectives: This study aimed to evaluate the prognostic value of baseline inflammatory, metabolic, and nutritional blood biomarkers and to construct an integrated dynamic prediction model for patient stratification. Design: This was a retrospective analysis conducted at a single center. Methods: We analyzed 191 SCLC patients treated between 2021 and 2024. Primary endpoints were overall survival (OS) and progression-free survival (PFS). The prognostic utility of inflammatory, metabolic, and nutritional blood biomarkers (neutrophil-to-lymphocyte ratio (NLR), lactate dehydrogenase (LDH), and prognostic nutritional index (PNI)) was systematically evaluated with quantitative comparisons across stage-treatment subgroups. We subsequently developed a novel composite metric, the LDH/Age (LA) ratio. Multivariable Cox regression was used to identify independent predictors, facilitating the construction and bootstrap validation of a nomogram and accompanying web-based calculator. Results: In the ES-SCLC cohort ( Conclusion: LDH, PNI, and NLR are established prognostic biomarkers for ES-SCLC patients undergoing CIT. Crucially, the novel LA ratio demonstrates enhanced predictive value for disease progression. The resulting web-based nomogram constitutes a practical, cost-effective mechanism for precise clinical risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.